226 related articles for article (PubMed ID: 17408910)
1. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
Kobayashi T; Goto R; Ito K; Mitsumori K
Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
[TBL] [Abstract][Full Text] [Related]
2. [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
Kobayashi T; Goto R; Hinotsu S; Ogawa O
Hinyokika Kiyo; 2013 Mar; 59(3):159-66. PubMed ID: 23633630
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of prostate cancer screening with prostate-specific antigen.
Imamura T; Yasunaga H
Int J Urol; 2008 Apr; 15(4):285-8. PubMed ID: 18380812
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
7. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
8. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
9. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
Kwon JS; Lu KH
Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
[TBL] [Abstract][Full Text] [Related]
11. Costs and benefits of prostate cancer screening. Investigators of the American Cancer Society--National Prostate Cancer Detection Project.
Littrup PJ; Goodman AC
In Vivo; 1994; 8(3):423-7. PubMed ID: 7803728
[TBL] [Abstract][Full Text] [Related]
12. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations.
Shen Y; Parmigiani G
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):529-32. PubMed ID: 15734983
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer.
Hassan C; Zullo A; Winn S; Morini S
Endoscopy; 2008 May; 40(5):414-21. PubMed ID: 18302080
[TBL] [Abstract][Full Text] [Related]
15. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
16. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
18. Impact of improvement in specificity of primary screening test on total cost of prostate cancer mass screening.
Kobayashi T; Goto R; Fukui T; Ogawa O
Int J Urol; 2007 Sep; 14(9):805-10. PubMed ID: 17760746
[TBL] [Abstract][Full Text] [Related]
19. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
Crawford ED; Abrahamsson PA
Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
[TBL] [Abstract][Full Text] [Related]
20. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
